CRSP · CRISPR Therapeutics AG

Track CRSP — free

$59.23 -1.67 (-2.74%) At close · Aug 26

Market Cap

$5.89B

96.69M

Up next

FQ3-26 quarter ends

~Sep 30, 2026 Est

Latest filing: 10-Q

filed Aug 3, 2026

Equibles Rating

blended score · not investment advice

Overall

Neutral

SellHoldBuy

Technical Strong Buy Momentum Strong Sentiment Bullish Fundamentals Fair Quant / Vol Very High

Market backdrop VIX 15.2 · calm Equity put/call 0.64

Technical

price trend

Strong Buy

50 / 200-day cross Golden cross

Price vs 200-day avg +12%

above

Price vs 50-day avg +11%

above

RSI (14) 61

neutral

MACD trend Positive

52-week position 46%

mid-range

Volume (OBV) Confirms

volume backs price

Momentum

relative strength

Strong

1-month return +24%

trailing

6-month return +3%

trailing

YTD return +13%

this year

Relative strength −9%

vs S&P · 6-mo

Sentiment

smart money

Bullish

Trend (MA cross) Golden cross

50d $53 › 200d $53 — 50d above 200d

Institutional flow Accumulating

+5% holders QoQ · +81 funds added

Insider flow Distributing

Net -$210.6K over 90 days · 100% sells

Short interest Falling

19.39% of float · ▼ -0.4% MoM · 15.6 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

524 holders — near 3-yr high, broad support

Squeeze score 77

high risk · 0–100

Fundamentals

Fair

Revenue growth +9170%

Y/Y

EPS growth −49%

Y/Y

Free cash flow $-345.9M

Balance sheet $347.6M

net cash

Quant / Vol

risk profile

Very High

Volatility 60%

annualized · 1-yr

Max drawdown −42%

past year

ATR 4.8%

of price · 14-day

Blended from price, momentum, positioning, fundamentals & volatility · daily-close · not investment advice. Market backdrop is context, not part of the score.

Guidance & track record

what management promised — and delivered

Prior guidance period ended · from the 8-K filed Nov 10, 2025

Total CASGEVY revenue · this year at least $100M

Guidance from company 8-Ks · delivered figures from as-reported statements · no analyst estimates involved.

Technicals

trend & momentum for long-term holders Strong Buy

0 · 3 · 4

50 / 200-day cross

Golden cross Bullish

Price vs 200-day avg

+12% Bullish

Price vs 50-day avg

+11% Bullish

RSI (14)

61 Neutral

MACD trend

Positive Bullish

52-week position

46% Neutral

Volume (OBV)

Confirms Neutral

Market signals — smart money & positioning

Bullish · 4 of 6

Trend (MA cross) Golden cross

50d $53 › 200d $53 — 50d above 200d

Institutional flow Accumulating

+5% holders QoQ · +81 funds added

Insider flow Distributing

Net -$210.6K over 90 days · 100% sells

Short interest Falling

19.39% of float · ▼ -0.4% MoM · 15.6 days cover

Volume signal Normal

Volume near normal

Institution breadth Multi-yr high

524 holders — near 3-yr high, broad support

Price context

position in its 52-week range

Range low $44 Now $59 · 46% Range high $77

vs 200-day avg +12% vs 50-day avg +11% 50-day above 200-day golden cross

Illustrative technical + ownership context — a signal mix, not investment advice.

Key metrics

the company's own KPIs, from written earnings releases and filings

Metric	Latest	Period	YoY
patients with SCD or TDT may be eligible for treatment with CASGEVY for the first time	5,500	second quarter of 2026	—
people globally have now initiated the CASGEVY treatment journey	500	Q1 2026	—
patients received infusions of CASGEVY	64	full year 2025	—
people with SCD or TDT initiated the treatment process with their first cell collection	147	full year 2025	—

Figures exactly as the company stated them in writing · click a metric with a to chart its history · period links open the stating document · "filing" marks figures stated in the 10-K/10-Q · YoY needs an exactly comparable prior-year period

Versus peers

Biotechnology — same industry group

Open screener →

Company	Mkt cap	YTD	Rev growth Y/Y	P/E	Short % shares
CRSP CRISPR Therapeutics AG this stock	$5.89B	+12.9%	+9169.8%	—	19.4%
VRTX Vertex Pharmaceuticals Inc / Ma	$138.72B	+20.7%	+46.2%	31.9	1.6%
REGN Regeneron Pharmaceuticals, Inc.	$83.89B	+5.6%	+20.8%	20.2	2.3%
ARGX Argenx SE	$63.81B	+24.5%	—	—	1.9%
CSLLY Csl Ltd	$60.07B	—	—	—	0.0%

Peers by industry group · P/E from as-reported trailing EPS · short % is of shares outstanding

At a glance

key data from every section

Ownership

Institutional Holders Reducing

Holders

524

% held: 81.4%
Net QoQ: -2.3M sh
Top holder: ARK Investment Management…

Held Float

View

Held by Funds

Fund positions

View

Short & Settlement

Short Interest Falling

Shares short

18.7M

Days to cover: 15.6d
Change: -70.8K sh

View

Short Volume

Short vol %

54%

As of: Aug 26, 2026

Short Total

View

Fails to Deliver

FTD shares

1.7K

Value: $81.6K
As of: Jul 31, 2026

View

Off-Exchange

Off-exchange %

50.2%

Week of: Jul 20, 2026

Off-exch Lit

View

Smart Money

Insider Trades Net selling

Net (90d)

-$210.6K

Buyers / Sellers: 0 / 1

Buyers Sellers

View

Congressional Trades Sell

Member

Thomas Suozzi

Amount: $50.0K–$100.0K
Traded: Sep 20, 2021

View

Financials

Revenue (FY)

$3.5M

Net income (FY): $-581.6M
EPS diluted: $-6.47

View

Filings

SEC Filings

Latest

8-K

Filed: Aug 3, 2026
This year: 12

View

Proposed Sales

Value

$2.1M

Shares: 35.0K
Filed: Jan 22, 2026

View

Exempt Offerings

Offering

$1.0M

Filed: Apr 10, 2020

View

Earnings & Events

Earnings Calls

Last call

Jun 9, 2026

View

Investor Relations

Performance

	5D	20D	120D	MTD	YTD
CRSP	-1.0%	+24.3%	+3.3%	+23.4%	+13.0%
SPY	-0.4%	+5.0%	+12.4%	+2.6%	+12.3%
vs SPY	-0.6%	+19.3%	-9.1%	+20.9%	+0.6%

Key facts CIK 1674416 CUSIP H17182108 13F (30d) 407 filings 403 filers Visit website Investor relations

CRSP · CRISPR Therapeutics AG

Price & Indicators

Up next

Equibles Rating

Guidance & track record

Technicals

Key metrics

Versus peers

At a glance

Performance